CD79A and nasopharyngeal carcinoma: miR-BART13-3p has a superior diagnostic performance than anti-EBNA1 IgA serology and EBV DNA load for NPC compared to asymptomatic EBV-infection (i.e. healthy donors and non-NPC tumors, EBV-associated diseases) [31].